Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Study of ASP7374 - Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age

Trial Profile

Phase 3 Study of ASP7374 - Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Jan 2017 According to an Astellas Pharma media release, the company will withdraw the application for marketing approval of ASP7374 which the company has filled in Japan as the company has terminated the development agreement with UMN Pharma.
    • 15 Jan 2014 Results from this trial were reported by Astellas Pharma and UMN Pharma, according to an UMN Pharma media release.
    • 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top